Thyia offers a self-administered cervical cancer screening kit that allows individuals to test for high-risk HPV in the privacy of their own homes. This solution addresses the barriers of traditional smear tests, such as discomfort and accessibility, by providing a clinically validated alternative that promotes early detection of cervical cancer.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional cervical cancer screening methods, such as Pap smears, can be uncomfortable, inconvenient, and create barriers to access, leading to lower screening rates, particularly among underserved populations. Many individuals find it difficult to schedule appointments, experience anxiety related to the procedure, or face geographical limitations in accessing healthcare facilities.
Solution
Thyia provides a self-administered cervical cancer screening kit that allows individuals to test for high-risk HPV from the convenience and privacy of their own homes. The kit offers a clinically validated alternative to traditional smear tests, promoting increased screening uptake and early detection of cervical cancer. Individuals can order the kit online, perform the test at their convenience, and mail the sample to an accredited lab for analysis. Results are then provided to the individual, along with information and support, and can be shared with their general practitioner.
Target Audience
The primary target audience includes individuals with a cervix over the age of 25 who are eligible for cervical cancer screening, particularly those who find traditional methods inconvenient, uncomfortable, or inaccessible.
Features
- Self-collection kit for convenient at-home sample collection
- Clinically validated HPV testing methodology
- Secure online ordering and result delivery
- Option to share results with a healthcare provider
- Designed to be as safe and effective as GP-led smear testing